Rapport Therapeutics reports Q2 results

2 days ago 1

Rapport Therapeutics press release (NASDAQ:RAPP): Q2 Net Loss for the second quarter of 2025 was $26.7 million, as compared to $18.1 million for the prior year period.
R&D expense was $22.7 million for the second quarter of 2025, as compared to $15.7 million for the prior year period.
Net loss per share of $0.75.

Recommended For You